Short answer
Rezolute, Inc. (RZLT) filed an 8-K current report with the SEC on October 14, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Rezolute announced an upLIFT study patient-enrollment update on October 14, 2026.
Rezolute, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Rezolute announced an upLIFT study patient-enrollment update on October 14, 2026
- Enrollment progress is material because it affects trial timelines and potential future clinical readouts
- Investors need Exhibit 99.1 for the substantive enrollment details and any revised expectations
- Disclosure includes forward-looking statements, increasing uncertainty around timing and study outcomes
Item EX-99.1 · Exhibit EX-99.1
- Phase 3 upLIFT enrollment complete, with topline results expected mid-December 2026
- Trial includes 16 participants with tumor hyperinsulinism and uncontrolled hypoglycemia requiring intravenous glucose
- Primary endpoint requires at least 50% reduction in glucose infusion rate, with statistical success requiring at least 56% responders
- Interim cohort showed 7 of 8 responders, each discontinuing intravenous glucose, supporting potential efficacy ahead of topline data
- Ersodetug was well-tolerated so far, but remains investigational and regulatory approval is not assured
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Rezolute, Inc. 8-K filings
Get the next RZLT 8-K as it lands
Follow RZLT for push alerts, or ask the research agent what this filing means.